IL17A and psoriasis: Another psoriatic patient on secukinumab was reported to present with atypical oral candidiasis, which improved remarkably following lowering the monthly dose of secukinumab to 150 mg [26] as well as another case of psoriasis who experienced co-existing chronic hyperplastic candidosis and an oral lichenoid lesion, as  side effects of the secukinumab therapy, which the patient was subjected to [27]. These reports emphasize the importance of IL-17 in the pathogenesis of PV as well as other superficial fungal infections.